Update information. Herein, we assembled a cohort composed of 254 CRC patients, including discovery cohort (N = 124) and validation cohort (N = 130), which received either chemotherapy (mainly FOLFOX therapy), chemoradiotherapy (mainly FOLFOX combined with radiotherapy), or targeted combination therapy (mainly FOLFOX combined with cetuximab).